Get To Know Us

Steven D. Goodman, Ph.D.

Steven D. Goodman, Ph.D.

Scientific Co-founder

Steven D. Goodman, Ph.D. is a Professor of Pediatrics at The Ohio State College of Medicine, Director of the Oral GI Microbiology Research Affinity Group, and Principal Investigator in the Center for Microbial Pathogenesis in the Abigail Wexner Research Institute of Nationwide Children’s Hospital. Dr. Goodman spent 20 years on the faculty at the Ostrow School of Dentistry of the University of Southern California where he was the Chair of the division of Biomedical Sciences and Director of the university-wide Microbial Systems Institute. He has published 79 peer review manuscripts and a recognized expert on the formation, structure, and function of Exopolymeric Substances (EPS) and gene regulation in bacterial biofilms. Dr. Goodman is a biochemist by training, receiving his doctoral degree from the Bloomberg School of Public Health at the Johns Hopkins University.

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.